Risankizumab

Eli Lilly missed Q3 estimates, lowered guidance; Merck beat estimates, initiated phase III study; Pfizer beat estimates, raised 2024 guidance; AbbVie beat estimates, acquired Aliada, collaborated with EvolveImmune; Novartis beat estimates, raised 2024 expectations, FDA approved Scemblix expansion.

HS is a chronic inflammatory disorder affecting hair follicles, characterized by painful, fluid-filled lesions. Humira was the sole FDA-approved therapy until Cosentyx's approval in Oct 2023. Off-label treatments like antibiotics precede biologics. This analysis covers HS treatment trends, Humira's integration, patient progression rates, and therapy combinations, using real-world claims data.

Native Hawaiian and Pacific Islander participation in clinical trials for top-selling drugs in 2024 was either unknown or minimal, with 60% of trials not reporting their numbers. All trials that did report had fewer participants than their population proportion, highlighting the need for purposeful strategies to include these groups, such as establishing recruitment sites in areas like Hawai‘i.

The biopharmaceutical industry saw a 2% upturn in aggregate market capitalization to $4.3 trillion in Q3 2024, driven by FDA approvals and interest rate cuts. Bristol-Myers Squibb, Gilead Sciences, Sanofi, AbbVie, and Alnylam Pharmaceuticals led with over 10% growth. Novo Nordisk and Merck faced declines due to FDA rejections and sales drops.

Johnson & Johnson's Carvykti and Tremfya sales grew in Q3, while Stelara faces biosimilar competition in 2025. J&J raised its sales guidance, with Tremfya seen as a potential successor to Stelara. Carvykti expanded its FDA approval and increased manufacturing capacity.

AbbVie and Novartis are recommended as 'forever' dividend stocks, with AbbVie overcoming Humira's patent loss and Novartis focusing on innovative medicines post-spinoff, both offering strong dividend yields.

Motley Fool contributors recommend AbbVie, Amgen, and Pfizer as top dividend stocks for October, highlighting their strong dividend histories, yields, and business strengths.

Skyrizi, approved for UC in June, has quickly gained market share over Omvoh, with over 90% of gastroenterologists aware of its approval and a majority already prescribing it. Skyrizi's efficacy and on-body injector device are preferred over Stelara. With Tremfya's recent UC approval, competition among IL-23 inhibitors is expected to intensify.

The UC market saw significant advancements with FDA approvals for AbbVie's Skyrizi and Johnson & Johnson's Tremfya. A Spherix survey revealed Skyrizi's rapid adoption and positive efficacy perceptions, capturing double the market share of Omvoh. Skyrizi's on-body injector received moderate to high satisfaction. With three IL-23 inhibitors now available, Spherix will monitor market dynamics to identify the preferred treatment.

UCB announces BE BOLD, a Phase 3b study comparing BIMZELX® (bimekizumab) with SKYRIZI® (risankizumab) in treating active psoriatic arthritis (PsA), marking the first head-to-head study in PsA evaluating an IL-17A and IL-17F inhibitor versus an IL-23 inhibitor. The primary endpoint is ACR50 at Week 16, aiming to provide meaningful comparison on inflamed joints. Top-line results expected in 2026.